Active substanceEthyl methylhydroxypyridine succinateEthyl methylhydroxypyridine succinate
Similar drugsTo uncover
  • Astrox
    solution w / m in / in 
    HOMEKSFARM LLC     Russia
  • Medomex®
    pills inwards 
       
  • Mexident®
    solution w / m in / in 
  • Mexidol®
    solution w / m in / in 
    FARMASOFT NPK, LLC     Russia
  • Mexidol®
    pills inwards 
    FARMASOFT NPK, LLC     Russia
  • Mexidol® FORTE 250
    pills inwards 
    FARMASOFT NPK, LLC     Russia
  • Mexicor®
    solution w / m in / in 
    EcoFarmInvest, LLC     Russia
  • Mexicor®
    capsules inwards 
    EcoFarmInvest, LLC     Russia
  • Mieleklek-Lekpharm
    solution w / m in / in 
    LEKFARM, SOOO     Republic of Belarus
  • Mexiprem ®
    solution w / m in / in 
    NIZHFARM, JSC     Russia
  • Mexiprem ®
    pills inwards 
    NIZHFARM, JSC     Russia
  • Mexinin®
    solution w / m in / in 
    BRENDFARMA, LLC     Russia
  • Metostabil
    solution w / m in / in 
    ATOLL, LLC     Russia
  • Metostabil
    pills inwards 
    ATOLL, LLC     Russia
  • MetucinWel
    solution w / m in / in 
    VELFARM, LLC     Republic of San Marino
  • Neurocardia
    solution w / m in / in 
  • Neurox®
    solution w / m in / in 
  • Proinin®
    solution w / m in / in 
  • Cerekard
    solution w / m in / in 
    EKOFARMPLUS, CJSC     Russia
  • Dosage form: & nbspfilm-coated tablets
    Composition:1 tablet, film-coated, contains:

    active substance: ethylmethyl hydroxypyridine succinate (2-ethyl-6-methyl-3-hydroxypyridine succinate) 125.0 mg;

    Excipients: lactose monohydrate 97.5 mg povidone 25.0 mg magnesium stearate 2.50 mg;

    film sheath: fall off II white 33G28435 7.5 mg (hypromellose 3.0 mg, titanium dioxide 1.875 mg, lactose monohydrate 1.575 mg, polyethylene glycol (macrogol) 0.6 mg, triacetin 0.45 mg).

    Description:Tablets are round, biconvex, covered with a coat, from white to white with a creamy shade of color.
    Pharmacotherapeutic group:Antioxidant
    ATX: & nbsp

    N.07.X.X   Other drugs for the treatment of diseases of the nervous system

    Pharmacodynamics:

    Mexidol® is an inhibitor of free-radical processes, a membrane protector possessing antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic action. The drug increases the resistance of the body to the effects of various damaging factors (shock, hypoxia and ischemia, cerebral circulation disorders, intoxication with alcohol and antipsychotic drugs (neuroleptics)).

    The mechanism of action of Mexidol® is due to its antioxidant, antihypoxic and membrane-protective action.It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the ratio of lipid-protein, reduces the viscosity of the membrane, increases its fluidity. Mexidol® modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase),

    Receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, contributes to the preservation of the structurally functional organization of biomembranes, the transport of neurotransmitters and the improvement of synaptic transmission. Meksidol® increases the content in the brain of dopamine. It causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition at oxidative processes in the Krebs cycle. Under conditions of hypoxia with an increase in the content of ATP and creatine phosphate, activation of energy-synthesizing functions of mitochondria, stabilization of cell membranes.

    The drug improves metabolism, and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membrane structures of blood cells; (erythrocytes and platelets) during hemolysis.Has a hypolipidemic effect, reduces the content of total cholesterol and low-density lipoproteins.

    Anti-stress effect is the normalization of post-stress behavior, somatovegetativnyh violations, restoration of the sleep-wake cycles, broken processes of learning and memory, and reducing degenerative morphological changes in different brain structures.

    Mexidol® has a pronounced antitoxic effect on withdrawal symptoms. It eliminates neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral, autonomic functions, as well as able to shoot cognitive impairment caused by prolonged use of ethanol and its abolition. Under, the influence Meksidola® amplified tranquilizing action, neuroleptics, antidepressants, hypnotics and anticonvulsants, to reduce their dose and reduce side effects. Mexidol® improves the functional state of the ischemic myocardium. In the context of coronary insufficiency increases collateral blood flow to ischemic myocardium, it helps to preserve the integrity of cardiomyocytes and maintaining their functional activity.Effectively restores myocardial contractility with reversible cardiac dysfunction.

    Pharmacokinetics:

    Quickly absorbed when taken orally. The maximum concentration at doses of 400-500 mg is 3.5-4.0 μg / ml. Quickly distributed in organs and tissues. The average retention time of the drug in the body with oral administration is 4.9-5.2 hours.

    Metabolised in the liver by glucuronconjugation. Five metabolites were identified: 3-hydroxypyridine phosphate - is formed in the liver and, with the participation of alkaline phosphatase, decomposes into phosphoric acid and 3-hydroxypyridine; The second metabolite, pharmacologically active, is formed in large quantities and is found in urine for 1-2 days after administration; 3rd - is excreted in large quantities with urine; 4-th and 5-th - glucuronconjugates.

    T1/2 when taken orally - 2.0-2.6 hours Quickly excreted in the urine mainly in the form of metabolites and in a small amount - unchanged. The most intense withdrawal within the first 4 hours after taking the drug. The indices of urinary excretion of unchanged drug and metabolites have individual variability.

    Indications:

    - Consequences of acute disorders of cerebral circulation, including after transient ischemic attacks, in the phase of subcompensation as preventive courses;

    - light craniocerebral injury, the consequences of craniocereberal trauma;

    - encephalopathy of various genesis (dyscirculatory, dismetabolic, posttraumatic, mixed);

    - syndrome of vegetative dystonia;

    - light cognitive disorders of atherosclerotic origin;

    - anxiety disorders in neurotic and neurosis-like states;

    - ischemic heart disease as part of complex therapy;

    - relief of withdrawal syndrome with alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, post-abstinence disorders;

    - state after acute intoxication by antipsychotic drugs;

    - asthenic conditions, as well as for the prevention, development, somatic diseases under the influence of extreme factors and loads;

    - influence of extreme (stressor) factors.

    Contraindications:

    Acute hepatic and / or renal failure, increased individual sensitivity to the drug.

    In connection with insufficient study of the effect of the drug - childhood, pregnancy, breastfeeding.

    Dosing and Administration:

    Inside, for 125-250 mg 3 times a day; the maximum daily dose is 800 mg (6 tablets).Duration of treatment - 2-6 week; for relief of alcohol withdrawal - 5-7 days. Treatment is stopped gradually, reducing the dose within 2-3 days.

    The initial dose is 125-250 mg (1-2 tablets) 1-2 times a day with a gradual increase to obtain a therapeutic effect; the maximum daily dose is 800 mg (6 tablets).

    The duration of therapy in patients with coronary heart disease is not less than 1,5-2 months. Repeated courses (on the recommendation of a doctor), preferably in the spring-autumn periods.

    Side effects:

    Perhaps the emergence of individual adverse reactions: dyspeptic or dyspeptic character, allergic reactions.

    Overdose:

    Overdose may develop drowsiness.

    Interaction:

    Mexidol® is combined with all drugs used to treat somatic diseases.

    Strengthens the action benzodiazepines, antidepressants, anxiolytics, anticonvulsants and antiparkinsonian means.

    Reduces the toxic effects of ethyl alcohol.

    Effect on the ability to drive transp. cf. and fur:

    During the treatment period, care must be taken when driving vehicles and taking other potentially hazardousActivities that require increased concentration and speed of psychomotor reactions.

    Form release / dosage:

    Tablets, film-coated, 125 mg.

    Packaging:

    10 tablets per contour cell packaging made of polyvinylchloride film and aluminum foil.

    For 1,2, 3, 4, 5 contour mesh packages together with instructions for use in a pack of cardboard.

    Storage conditions:

    Store in a dry place protected from light at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date indicated on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-002063/07
    Date of registration:09.08.2007 / 08.12.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:FARMASOFT NPK, LLC FARMASOFT NPK, LLC Russia
    Manufacturer: & nbsp
    Representation: & nbspFARMASOFT NPK LLC FARMASOFT NPK LLC Russia
    Information update date: & nbsp27.04.2018
    Illustrated instructions
      Instructions
      Up